# Optimi Health Corp.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Optimi Health Corp.).

## Overview

Optimi Health Corp. is a Canada-based pharmaceutical manufacturer focused on GMP-grade psychedelic drug products, including botanical psilocybin and MDMA-based formulations. The company produces active pharmaceutical ingredients and finished dosage forms at its own licensed facility in British Columbia and supplies regulated clinical and therapeutic programs in international markets.

## Products & services

• GMP-grade botanical psilocybin drug products
• MDMA drug products
• Active pharmaceutical ingredients (APIs)
• Finished dosage forms for clinical use
• Clinical trial and special access supply
• Manufacturing, formulation, encapsulation, packaging

- **Botanical psilocybin products** (50%) — Validated psilocybin-based drug products made for regulated therapeutic and research use.
- **MDMA drug products** (25%) — GMP-grade MDMA products supplied for clinical research and special access programs.
- **Active pharmaceutical ingredients** (10%) — In-house produced APIs used as inputs for finished psychedelic drug products.
- **Finished dosage forms** (10%) — Encapsulated, packaged drug products prepared for regulated patient access and trials.
- **Manufacturing and supply services** (5%) — Licensed GMP manufacturing, formulation, and export support for clinical customers.

- GMP-grade botanical psilocybin drug products
- MDMA drug products
- Active pharmaceutical ingredients (APIs)
- Finished dosage forms for clinical use
- Clinical trial and special access supply
- Manufacturing, formulation, encapsulation, packaging

## Customers

Optimi sells to regulated clinical and therapeutic programs rather than broad consumer markets. Its buyers include clinical research organizations, special access program users, and healthcare channels that require GMP-grade psychedelic products with documented quality and traceability. The company also serves patients in jurisdictions where authorized-prescriber or special-access pathways allow use of these drugs.

- **Clinical research organizations** (primary) — Buy psilocybin and MDMA supply for controlled clinical trials and research protocols.
- **Special access programs** (primary) — Buy finished products for patients who can access psychedelic therapies through regulated pathways.
- **Authorized prescribers** (secondary) — Use supplied drug products for prescribed treatment under country-specific access schemes.
- **Therapeutic program operators** (secondary) — Source GMP-grade dosage forms and APIs for supervised mental health treatment settings.

- Clinical research organizations needing trial supply
- Special access programs for patient treatment
- Authorized prescribers using regulated psychedelic products
- Therapeutic programs requiring GMP-grade drug supply
- Healthcare buyers that need validated APIs and dosage forms

## Geography

Optimi manufactures in Princeton, British Columbia, Canada, where its licensed GMP facility and in-house production chain are located. The company sells into regulated markets internationally, with reported patient access in Australia and Canada and an initial shipment into the United Kingdom. Its business is therefore shaped by cross-border pharmaceutical regulation, import/export controls, and country-specific access pathways.

- **Canada** (34%) — Manufacturing base and patient access via Special Access Program
- **Australia** (33%) — Reported patient access under Authorized Prescriber Scheme
- **United Kingdom** (33%) — Initial shipment reported into the UK market

- Manufacturing is based in Princeton, British Columbia, Canada
- International sales to regulated psychedelic markets
- Australia is an active patient-access market
- Canada access via the Special Access Program
- United Kingdom shipment indicates expanding export reach

## Strategy

Optimi’s strategy is built around controlling the full production chain, from cultivation and extraction through formulation, capsule filling, packaging, and export. That vertical integration supports both commercial supply and clinical-trial supply from the same GMP facility, which is important in a market where regulated production capability is a key barrier to entry. The company is also focused on expanding into additional regulated jurisdictions while maintaining licensed, traceable manufacturing.

- **Scale GMP production and export capability** (short-term) — A controlled manufacturing platform is the core competitive asset in psychedelic pharma.
- **Broaden regulated market access** (medium-term) — Growth depends on approvals and access pathways in multiple countries.
- **Serve both research and patient-access channels** (medium-term) — Dual-use manufacturing can improve facility utilization and customer reach.

- Run a vertically integrated GMP manufacturing platform
- Supply both commercial markets and clinical trials
- Expand access across regulated international jurisdictions
- Use one facility and licence across multiple product types
- Maintain quality, traceability, and regulatory compliance

## Risks

Optimi depends on highly regulated access pathways, so demand can shift with changes in national health rules, import controls, and prescribing frameworks. The business also faces execution risk around GMP quality, product consistency, and scaling a specialized manufacturing model across multiple countries. As a psychedelic-drug supplier, it is exposed to the broader uncertainty of a still-developing therapeutic market and the possibility that clinical adoption progresses more slowly than expected.

- **Regulatory dependency** [high] — Sales depend on special-access, prescribing, and clinical-trial rules in each jurisdiction.
- **GMP quality and manufacturing compliance** [high] — The business model relies on producing validated pharmaceutical products in-house.
- **Market adoption risk** [medium] — Psychedelic therapies are still an emerging treatment category with evolving acceptance.
- **Cross-border logistics** [medium] — Finished drug products and APIs must move across borders under controlled conditions.

- Regulatory approvals govern who can buy and use the products
- Cross-border shipment depends on import/export and pharma rules
- GMP compliance failures could disrupt supply and customer trust
- Market adoption of psychedelic therapies remains uncertain
- Customer concentration in niche clinical channels may be material

## Accounting

Optimi’s reporting involves judgment-heavy estimates typical of a specialized pharmaceutical manufacturer, including going-concern assessment and provisions or contingencies. Because it consolidates multiple subsidiaries and operates a regulated production facility, investors should watch how inventory, production costs, and capitalized manufacturing assets are measured. IFRS fair-value and estimate sensitivity can matter as the company builds out specialized equipment and may carry obligations or contingencies tied to its operating license and product programs.

- **Going concern** — Can affect valuation, disclosure, and financial statement presentation
- **Provisions and contingencies** — May change liabilities and period expenses
- **Consolidation of subsidiaries** — Affects reported assets, liabilities, and operating results
- **Fair value measurements** — Can create non-cash gains or losses in profit or loss

- Going-concern assessment is a key estimate
- Provisions and contingencies may affect liabilities
- Consolidation includes Optimi Labs and Optimi Nutraceuticals
- Historical-cost accounting affects plant and equipment values
- Fair-value measurements apply to certain financial instruments

---

*Last updated: 2026-09-28T12:13:33.134917+00:00*